ERAS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Erasca Inc (ERAS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has positive catalysts and strong analyst support, the lack of recent financial growth, insider selling, and no significant trading signals suggest it is better to wait for more clarity on the company's clinical developments and financial performance.
The technical indicators are mixed. The MACD histogram is negative (-0.0913), indicating bearish momentum, while the RSI (56.124) is neutral. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading close to its resistance level (R1: 15.896). Key support is at 13.237.
Strong analyst support with multiple price target increases (ranging from $10 to $
and positive sentiment around the potential of ERAS-
Large addressable market for RAS-mutant cancer treatments, with analysts expecting differentiation and competitive clinical profiles.
Clinical trial and supply agreement with Tango Therapeutics, enhancing combination therapy flexibility.
Insider selling by the Chief Medical Officer, reducing her direct holdings to zero.
Financial performance shows no revenue growth and a decline in net income and EPS in Q4
No recent congress trading data or significant hedge fund activity.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income decline to -$29.09M (-9.74% YoY), and a drop in EPS to -0.1 (-9.09% YoY). Gross margin remains at 0%.
Analysts are highly optimistic, with multiple firms raising price targets significantly. JPMorgan, Guggenheim, and others highlight the potential of ERAS-0015 and the large addressable market. The consensus rating is Overweight/Buy.
